Much Maligned Manufacturing Site Trips Up Scholar Rock’s Spinal Muscular Atrophy Drug

The FDA has rejected Scholar Rock's investigational spinal muscular atrophy drug, apitegromab, not due to efficacy or safety concerns, but because of unresolved manufacturing deficiencies at a third-party fill-finish site, Catalent Indiana LLC, recently acquired by Novo Nordisk. The regulator cited long-standing issues at the facility, including poor quality control, contamination (e.g., cat hair, bacteria), and substandard equipment maintenance, which have also impacted Regeneron's drug applications. While Scholar Rock plans an expedited resubmission, the uncertain timeline for resolution at the facility led to a 12.5% drop in its shares pre-market, despite the absence of clinical approvability concerns being a mild positive.

Analysis

The FDA's rejection of Scholar Rock's (SRRK) apitegromab is a manufacturing-centric event, not a clinical failure. The Complete Response Letter cites deficiencies at a Catalent Indiana LLC fill-finish site, recently acquired by Novo Nordisk (NVO), without raising concerns about the drug's efficacy or safety. This is a crucial distinction, as the positive Phase III SAPPHIRE study data remains valid, which BMO Capital Markets notes is a 'mild positive'. However, the market's reaction, a 12.5% pre-market decline in SRRK shares, reflects the significant uncertainty surrounding the resubmission timeline. The issues at the Catalent facility are severe and systemic, with FDA reports documenting long-standing problems like poor quality control, bacterial contamination, and pest infestations dating back to June 2022. This manufacturing bottleneck is not isolated to Scholar Rock; it has also delayed regulatory decisions for Regeneron's (REGN) high-dose Eylea formulation. The situation concentrates risk on Novo Nordisk's ability to remediate the newly acquired facility, making the timeline for resolution the primary variable for affected companies.

Key Decisions for Investors

• For Scholar Rock (SRRK) investors, the focus should shift from clinical risk to manufacturing timeline risk; monitor for any guidance on the remediation of the Catalent facility, as this is now the primary catalyst for resolving the approval delay.
• The recurring issues at the Catalent Indiana plant represent a material operational liability for Catalent (CTLT) and its new owner, Novo Nordisk (NVO), potentially impacting a wider portfolio of clients and creating headline risk.
• This event serves as a reminder of supply chain vulnerabilities in the biotech sector; investors should assess the manufacturing counterparty risk for companies reliant on single-source contract manufacturers, especially those with exposure to the specific Catalent facility, including Regeneron (REGN).